Table 1.
Synoptic overview of the patient population.
| Patients | 116 | |
|---|---|---|
| IDH1 wild type GBM WHO IV | 116 | |
| Female | 57 | 49.1% |
| Male | 59 | 50.9% |
| GTR | 81 | 69.8% |
| PR | 18 | 15.5% |
| Biopsy | 17 | 14.7% |
| Surgery + Radio-chemotherapy | 116 | |
| Deceased | 110 | 94.8% |
| Alive | 6 | 5.1% |
| Progression Disease (PD) | 92 | 79.3% |
| Alive with no evidence of PD | 6 | 5.1% |
| Deceased with no evidence of PD | 18 | 15.5% |
| MGMT methylated | 41 | 35.3% |
| MGMT non-methylated | 71 | 61.2% |
| MGMT non definable | 4 | 3.4% |
| MGMT protein expression positive | 54 | 46.5% |
| MGMT protein expression negative | 44 | 37.9% |
| MGMT expression not evaluable | 18 | 15.5% |
GBM, Glioblastoma; GTR, Gross Total Resection; MGMT, methylguanine-DNA methyltransferase; PR, Partial Resection.